TOX 21: New Dimensions of Toxicity Testing
نویسنده
چکیده
منابع مشابه
Current status of the Gene-Tox Program.
The U.S. Environmental Protection Agency's Gene-Tox Program is a multiphased effort to review and evaluate the existing literature in assay systems available in the field of genetic toxicology. The first phase of the Gene-Tox Program selected assay systems for evaluation, generated expert panel reviews of the data from the scientific literature, and recommended testing protocols for the systems...
متن کاملToxicity Prediction using Deep Learning
Everyday we are exposed to various chemicals via food additives, cleaning and cosmetic products and medicines — and some of them might be toxic. However testing the toxicity of all existing compounds by biological experiments is neither financially nor logistically feasible. Therefore the government agencies NIH, EPA and FDA launched the Tox21 Data Challenge within the “Toxicology in the 21st C...
متن کاملNanoE-Tox: New and in-depth database concerning ecotoxicity of nanomaterials
The increasing production and use of engineered nanomaterials (ENMs) inevitably results in their higher concentrations in the environment. This may lead to undesirable environmental effects and thus warrants risk assessment. The ecotoxicity testing of a wide variety of ENMs rapidly evolving in the market is costly but also ethically questionable when bioassays with vertebrates are conducted. Th...
متن کاملLessons learned from alternative methods and their validation for a new toxicology in the 21st century.
Europe and the United States further the development of new toxicological tools in different ways. While the replacement of animal tests has been promoted strongly in Europe over the last decades (following the 3Rs principles--reduce, replace, refine), in the United States the vision for a toxicology in the 21st century (Tox-21c), which was prompted by the National Research Council document onl...
متن کاملSuccessful Drug Development Despite Adverse Preclinical Findings Part 2: Examples
To illustrate the process of addressing adverse preclinical findings (APFs) as outlined in the first part of this review, a number of cases with unexpected APF in toxicity studies with drug candidates is discussed in this second part. The emphasis is on risk characterization, especially regarding the mode of action (MoA), and risk evaluation regarding relevance for man. While severe APFs such a...
متن کامل